Effects of food on the bioavailability of CGS 16617, an angiotensin-converting enzyme inhibitor, in healthy subjects.
CGS 16617, a direct-acting angiotensin-converting-enzyme inhibitor, was administered as a single dose of 20 mg in aqueous solution to 12 healthy male volunteers on two occasions in a randomized, cross-over design study. On one occasion, the dose was administered after an overnight fast; on the other occasion, it was administered after subjects ate a standard breakfast. Administration of CGS 16617 after food was associated with statistically significant decreases in peak plasma concentrations (58%) and areas under the plasma concentration-time curves (23%) compared with drug administration in the fasted state. Also, the time to peak plasma concentration was increased (57%) in a statistically significant manner when CGS 16617 was administered after food. Thus, the ingestion of food decreased both the rate and extent of absorption of this drug, but the mechanism of the interaction is unknown at present.
Choi
R L
RL
Development Department, Ciba-Geigy Corporation, Ardsley, NY 10502.
Kochak
G M
GM
Reydel-Bax
P
P
Nelson
E B
EB
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D001552:Benzazepines / Q000493:pharmacokinetics*; D001682:Biological Availability; D005502:Food; D006801:Humans; D008297:Male
D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; C052134:libenzapril